1096 / 1816
START Trial B –
40Gy in 15# of 2.67Gy was as effective in terms of tumour control &
adverse effects as 50Gy in 25# of 2Gy.
FAST trial
28.5Gy in 5# of 5.7Gy appears equivalent to 50Gy/25F in terms of
change in breast appearance at 2 years and late adverse effects
in breast at a median of 3.1 years.
This is unlikely to be the limit of hypofractionation – how far can
we go?